Mylan (NASDAQ:MYL) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Several other research analysts also recently commented on MYL. Cowen reaffirmed a “hold” rating and issued a $30.00 target price (down from $43.00) on shares of Mylan in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Wells Fargo & Company set a $30.00 target price on shares of Mylan and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $32.00 price target (down previously from $33.00) on shares of Mylan in a report on Thursday, August 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $45.00 price target (down previously from $50.00) on shares of Mylan in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. Mylan has an average rating of “Buy” and a consensus price target of $41.49.

Mylan (NASDAQ MYL) opened at $38.12 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. Mylan has a one year low of $29.39 and a one year high of $45.87. The company has a market cap of $19,600.00, a price-to-earnings ratio of 7.85, a P/E/G ratio of 2.02 and a beta of 1.38.

Mylan (NASDAQ:MYL) last issued its earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. During the same period in the previous year, the firm earned $1.38 earnings per share. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. analysts anticipate that Mylan will post 4.56 EPS for the current year.

Hedge funds have recently made changes to their positions in the company. Canada Pension Plan Investment Board boosted its holdings in shares of Mylan by 99.5% during the 3rd quarter. Canada Pension Plan Investment Board now owns 1,217,413 shares of the company’s stock valued at $38,189,000 after buying an additional 607,094 shares in the last quarter. FMR LLC raised its position in shares of Mylan by 19.8% in the 2nd quarter. FMR LLC now owns 813,267 shares of the company’s stock worth $31,572,000 after purchasing an additional 134,258 shares during the last quarter. Swiss National Bank raised its position in shares of Mylan by 3.1% in the 2nd quarter. Swiss National Bank now owns 1,661,842 shares of the company’s stock worth $64,513,000 after purchasing an additional 50,100 shares during the last quarter. Vivaldi Asset Management LLC purchased a new position in shares of Mylan in the 2nd quarter worth about $5,098,000. Finally, Toronto Dominion Bank raised its position in shares of Mylan by 28.2% in the 3rd quarter. Toronto Dominion Bank now owns 200,017 shares of the company’s stock worth $6,274,000 after purchasing an additional 43,943 shares during the last quarter. Hedge funds and other institutional investors own 73.86% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/12/02/mylan-myl-lifted-to-buy-at-valuengine.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.